Kezar Life Sciences (KZR) Stock Forecast, Price Target & Predictions
KZR Stock Forecast
Kezar Life Sciences stock forecast is as follows: an average price target of $17.50 (represents a 3042.96% upside from KZR’s last price of $0.56) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
KZR Price Target
The average price target for Kezar Life Sciences (KZR) is $17.50 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $21.00 to $14.00. This represents a potential 3042.96% upside from KZR's last price of $0.56.
KZR Analyst Ratings
According to 2 Wall Street analysts, Kezar Life Sciences's rating consensus is 'Buy'. The analyst rating breakdown for KZR stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Kezar Life Sciences Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 12, 2022 | - | H.C. Wainwright | $21.00 | $9.76 | 115.16% | 3671.55% |
| May 04, 2022 | - | Wells Fargo | $14.00 | $7.94 | 76.36% | 2414.37% |
The latest Kezar Life Sciences stock forecast, released on Aug 12, 2022 by H.C. Wainwright company, set a price target of $21.00, which represents a 115.16% increase from the stock price at the time of the forecast ($9.76), and a 3671.55% increase from KZR last price ($0.56).
Kezar Life Sciences Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.56 | $0.56 | $0.56 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Kezar Life Sciences stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Kezar Life Sciences's last price of $0.56. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Aug 14, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Jan 03, 2023 | Wells Fargo | Overweight | Overweight | Hold |
| Jun 28, 2022 | Wells Fargo | Overweight | Overweight | Hold |
Kezar Life Sciences's last stock rating was published by Cowen & Co. on Aug 14, 2024. The company gave KZR a "Buy" rating, the same as its previous rate.
Kezar Life Sciences Financial Forecast
Kezar Life Sciences Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $7.00M |
| Avg Forecast | - | - | - | - | $2.50M | $2.50M | $2.50M | $2.50M | $1.60M | $800.00K | $750.00K | $666.67K | $1.00M | $166.67K |
| High Forecast | - | - | - | - | $2.50M | $2.50M | $2.50M | $2.50M | $1.60M | $800.00K | $750.00K | $666.67K | $1.00M | $166.67K |
| Low Forecast | - | - | - | - | $2.50M | $2.50M | $2.50M | $2.50M | $1.60M | $800.00K | $750.00K | $666.67K | $1.00M | $166.67K |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 42.00% |
Kezar Life Sciences's average Quarter revenue forecast for Dec 23 based on 3 analysts is $1.00M, with a low forecast of $1.00M, and a high forecast of $1.00M. KZR's average Quarter revenue forecast represents a -85.71% decrease compared to the company's last Quarter revenue of $7.00M (Sep 23).
Kezar Life Sciences EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-28.12M | $-25.53M |
| Avg Forecast | - | - | - | - | $1.50M | $1.50M | $1.50M | $1.50M | $960.00K | $480.00K | $450.00K | $400.00K | $600.00K | $100.00K |
| High Forecast | - | - | - | - | $1.50M | $1.50M | $1.50M | $1.50M | $960.00K | $480.00K | $450.00K | $400.00K | $600.00K | $100.00K |
| Low Forecast | - | - | - | - | $1.50M | $1.50M | $1.50M | $1.50M | $960.00K | $480.00K | $450.00K | $400.00K | $600.00K | $100.00K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -46.87% | -255.27% |
undefined analysts predict KZR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Kezar Life Sciences's previous annual EBITDA (undefined) of $NaN.
Kezar Life Sciences Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-32.26M | $-23.10M |
| Avg Forecast | $-28.80M | $-28.23M | $-27.49M | $-26.78M | $-20.03M | $-20.40M | $-20.40M | $-20.76M | $-23.92M | $-22.95M | $-23.29M | $-24.28M | $-27.65M | $-25.97M |
| High Forecast | $-28.80M | $-28.23M | $-27.49M | $-26.78M | $-20.03M | $-20.40M | $-20.40M | $-20.76M | $-23.92M | $-17.59M | $-23.29M | $-24.28M | $-24.10M | $-25.97M |
| Low Forecast | $-28.80M | $-28.23M | $-27.49M | $-26.78M | $-20.03M | $-20.40M | $-20.40M | $-20.76M | $-23.92M | $-29.07M | $-23.29M | $-24.28M | $-30.48M | $-25.97M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.17% | 0.89% |
Kezar Life Sciences's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. KZR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Kezar Life Sciences SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $5.48M | $8.79M |
| Avg Forecast | - | - | - | - | $3.82M | $3.82M | $3.82M | $3.82M | $2.44M | $1.22M | $1.15M | $1.02M | $1.53M | $254.64K |
| High Forecast | - | - | - | - | $3.82M | $3.82M | $3.82M | $3.82M | $2.44M | $1.22M | $1.15M | $1.02M | $1.53M | $254.64K |
| Low Forecast | - | - | - | - | $3.82M | $3.82M | $3.82M | $3.82M | $2.44M | $1.22M | $1.15M | $1.02M | $1.53M | $254.64K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 3.59% | 34.52% |
Kezar Life Sciences's average Quarter SG&A projection for Mar 24 is $1.02M, based on 1 Wall Street analysts, with a range of $1.02M to $1.02M. The forecast indicates a -81.41% fall compared to KZR last annual SG&A of $5.48M (Dec 23).
Kezar Life Sciences EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.44 | $-0.32 |
| Avg Forecast | $-0.40 | $-0.39 | $-0.38 | $-0.37 | $-0.28 | $-0.28 | $-0.28 | $-0.28 | $-0.33 | $-0.32 | $-0.32 | $-0.33 | $-0.38 | $-0.36 |
| High Forecast | $-0.40 | $-0.39 | $-0.38 | $-0.37 | $-0.28 | $-0.28 | $-0.28 | $-0.28 | $-0.33 | $-0.24 | $-0.32 | $-0.33 | $-0.33 | $-0.36 |
| Low Forecast | $-0.40 | $-0.39 | $-0.38 | $-0.37 | $-0.28 | $-0.28 | $-0.28 | $-0.28 | $-0.33 | $-0.40 | $-0.32 | $-0.33 | $-0.42 | $-0.36 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.16% | 0.90% |
According to undefined Wall Street analysts, Kezar Life Sciences's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to KZR previous annual EPS of $NaN (undefined).
Kezar Life Sciences Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KZR | Kezar Life Sciences | $0.56 | $17.50 | 3025.00% | Buy |
| IPSC | Century Therapeutics | $1.46 | $20.00 | 1269.86% | Buy |
| NGM | NGM Biopharmaceuticals | $1.54 | $16.50 | 971.43% | Buy |
| LYEL | Lyell Immunopharma | $1.17 | $9.50 | 711.97% | Hold |
| HOWL | Werewolf Therapeutics | $2.02 | $12.00 | 494.06% | Buy |
| NKTX | Nkarta | $5.32 | $21.60 | 306.02% | Buy |
| STTK | Shattuck Labs | $3.50 | $12.00 | 242.86% | Buy |
| MLYS | Mineralys Therapeutics | $11.23 | $30.00 | 167.14% | Buy |
| FHTX | Foghorn Therapeutics | $7.53 | $18.00 | 139.04% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| DSGN | Design Therapeutics | $4.67 | $9.67 | 107.07% | Buy |
| KROS | Keros Therapeutics | $52.51 | $105.00 | 99.96% | Buy |
| LRMR | Larimar Therapeutics | $8.05 | $14.50 | 80.12% | Buy |
| CGEM | Cullinan Oncology | $17.98 | $32.00 | 77.98% | Buy |
| BOLT | Bolt Biotherapeutics | $0.65 | $1.00 | 53.85% | Hold |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
| NRIX | Nurix Therapeutics | $23.33 | $27.57 | 18.17% | Buy |
| KYMR | Kymera Therapeutics | $45.40 | $51.10 | 12.56% | Buy |
| IKNA | Ikena Oncology | $1.69 | $1.33 | -21.30% | Buy |
KZR Forecast FAQ
Is Kezar Life Sciences a good buy?
Yes, according to 2 Wall Street analysts, Kezar Life Sciences (KZR) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of KZR's total ratings.
What is KZR's price target?
Kezar Life Sciences (KZR) average price target is $17.5 with a range of $14 to $21, implying a 3042.96% from its last price of $0.557. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Kezar Life Sciences stock go up soon?
According to Wall Street analysts' prediction for KZR stock, the company can go up by 3042.96% (from the last price of $0.557 to the average price target of $17.5), up by 3671.55% based on the highest stock price target, and up by 2414.37% based on the lowest stock price target.
Can Kezar Life Sciences stock reach $1?
KZR's average twelve months analyst stock price target of $17.5 supports the claim that Kezar Life Sciences can reach $1 in the near future.
What are Kezar Life Sciences's analysts' financial forecasts?
Kezar Life Sciences's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $10M (high $10M, low $10M), average EBITDA is $6M (high $6M, low $6M), average net income is $-81.587M (high $-81.587M, low $-81.587M), average SG&A $15.28M (high $15.28M, low $15.28M), and average EPS is $-1.12 (high $-1.12, low $-1.12). KZR's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-111M (high $-111M, low $-111M), average SG&A $0 (high $0, low $0), and average EPS is $-1.528 (high $-1.528, low $-1.528).
Did the KZR's actual financial results beat the analysts' financial forecasts?
Based on Kezar Life Sciences's last annual report (Dec 2023), the company's revenue was $7M, beating the average analysts forecast of $1.17M by 500.00%. Apple's EBITDA was $-111M, missing the average prediction of $700K by -16017.71%. The company's net income was $-102M, beating the average estimation of $-53.616M by 90.00%. Apple's SG&A was $26.54M, beating the average forecast of $1.78M by 1388.95%. Lastly, the company's EPS was $-0.0014, missing the average prediction of $-0.736 by -99.81%. In terms of the last quarterly report (Sep 2023), Kezar Life Sciences's revenue was $7M, beating the average analysts' forecast of $166.67K by 4099.99%. The company's EBITDA was $-25.527M, missing the average prediction of $100K by -25627.00%. Kezar Life Sciences's net income was $-23.103M, missing the average estimation of $-25.968M by -11.03%. The company's SG&A was $8.79M, beating the average forecast of $254.64K by 3351.57%. Lastly, the company's EPS was $-0.32, missing the average prediction of $-0.356 by -10.23%